Implementation of an Integrated Precision Care Pathway Program for Metastatic Prostate Cancer
Implementation of an Integrated Precision Care Pathway Program for Metastatic Prostate Cancer supports healthcare teams' quality improvement work to improve testing and coordinated care in Mainland China.
Browse similar grants
Funder: Pfizer Inc.
Due Dates: January 14, 2027, at 11:59 p.m. EST (Submission) | March 26, 2027 (Anticipated notification) | June 25, 2027 (Anticipated start) | June 25, 2029 (Anticipated end)
Funding Amounts: Up to $55,000 per project for up to two years; estimated total budget of $220,000
Summary: Supports practice-based quality improvement in metastatic prostate cancer testing, care coordination, patient engagement, and safety management in Mainland China.
Key Information: Organizations must be legally able to receive funding directly from Pfizer Investment Co., Ltd.; clinical research is excluded.
Description
Pfizer’s competitive quality improvement program supports healthcare organizations implementing integrated precision care pathways for patients with metastatic prostate cancer in Mainland China. It targets measurable gaps in homologous recombination repair (HRR) biomarker testing, multidisciplinary care coordination, patient engagement, and treatment-related safety management. Projects should translate existing evidence into routine practice through targeted workflow and system-level improvements in academic and community settings.
The program seeks sustainable, scalable improvements in testing pathways, proactive adverse event management, communication, and health literacy. It supports formal quality improvement rather than clinical research or evaluations of therapeutic efficacy or diagnostic performance. Interventions must be non-promotional, guideline-concordant, locally compliant, and independent of Pfizer products or branded treatment pathways.
